swapnil hiremath

November 28, 2023

Background

Optimizing “Sparse” Treatments for FSGS

swapnil hiremath

November 28, 2023

Background

This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?

Divya Bajpai

November 27, 2023

The Duplex Study - Visual Abstract

Divya Bajpai

November 27, 2023

Checkout the role of Sparsentan in FSGS - The Duplex Trial VA by NSMC Intern Pallavi Prasad

swapnil hiremath

November 19, 2023

Background

BEATing Calciphylaxis with an Adaptive Platform design

swapnil hiremath

November 19, 2023

Background

BEATing  Calciphylaxis with an Adaptive Platform design

This week on #NephTrials, we will discuss platform trials, anchoring the discussion to the BEAT-Calci trial, which has a number of interesting design features.

Jamie Willows

November 17, 2023

tweetorial

Salt in the wounds?

Jamie Willows

November 17, 2023

tweetorial

Fascinating observational study on hyponatraemia correction rates this week, catch-up here.

Welcome to #TenTweetNephJC

✳️10 tweet #NephJC catch-up ✳️

The challenge has been declared to the concept that rate of hyponatraemia correction is as vital as nephrologists have been telling you - to know if you agree, you need to know the studies the challenge is based upon🧵👇 pic.twitter.com/S5XVH9QqRb
— Nephrology Journal Club (@NephJC) November 17, 2023

swapnil hiremath

November 14, 2023

Visual Abstract

The ENAKT-LKD Visual Abstract

swapnil hiremath

November 14, 2023

Visual Abstract

Another sterlling visual abstract from Milagros Flores

Cristina Adriana Popa

November 14, 2023

Background

Unlocking the door to living kidney donor paradise?

Cristina Adriana Popa

November 14, 2023

Background

Unlocking the door to living kidney donor paradise?

This week, nephrologists hope they found the key to no-dialysis-land, where kindness and detailed, multistep interventions make the path to kidney transplant much easier. This was foreseen in our Freely Filtered episode and disputed during #KidneyWK 2023 late-breaking clinical trials session. Still, when it comes to RCTs’ results, will it be Deja Vu or a happy ending?